Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure

BMC Cardiovascular Disorders

Research Article

Yanfen Shi¹  Andreanne Chabot¹  Bao Hua Jiang¹  Jocelyn Dupuis²  Jean-Claude Tardif² 

[1] Research Center, Montreal Heart Institute/Université de Montréal, 5000 Bélanger Street, H1T 1C8, Montreal, Quebec, Canada;Research Center, Montreal Heart Institute/Université de Montréal, 5000 Bélanger Street, H1T 1C8, Montreal, Quebec, Canada;Department of Medicine, Université de Montréal, 2910 boul. Edouard-Montpetit, H3T 1J7, Montreal, Quebec, Canada;

关键词: spironolactone;    pulmonary heart disease;    pulmonary hypertension;    myofibroblasts;   

DOI  :  10.1186/1471-2261-11-72

 received in 2011-09-20, accepted in 2011-12-02,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundThe mechanisms of benefit of mineralocorticoid receptors antagonists in congestive heart failure (CHF) are still debated. We hypothesized that aldosterone contributes to pulmonary remodelling and right ventricular (RV) dysfunction associated with CHF by stimulation of lung myofibroblasts (MYFs) proliferation.MethodsRats with moderate to large myocardial infarcts (MI) and CHF were studied. Two weeks after MI, spironolactone 100 mg/kg/day (n = 21) or no treatment (n = 24) were given for 3 weeks and compared to sham (n = 8).ResultsInfarct size was similar by ultrasound and pathologic measures in both MI groups.The MI-untreated group developed important lung remodelling with nearly doubling of dry lung weight (p < 0.01), reduced left ventricular (LV) fractional shortening (16 ± 2% vs. 53 ± 1%; mean ± SEM, p < 0.0001), pulmonary hypertension (RV systolic pressure: 40 ± 3 mmHg vs. 27 ± 1 mmHg, p < 0.01) and RV hypertrophy (RV/(LV + septum): 38 ± 3% vs. 24 ± 1%, p < 0.05). Spironolactone had no effect on these parameters and did not improve LV or RV performance (tricuspid annular plane systolic excursion and RV myocardial performance index) measured by echocardiography. CHF induced a restrictive respiratory syndrome with histological lung fibrosis: this was also unaffected by spironolactone. Finally, isolated lung MYFs did not proliferate after exposure to aldosterone.ConclusionAldosterone does not significantly contribute to pulmonary remodelling and RV dysfunction associated with CHF. Other mechanisms are responsible for the beneficial effects of spironolactone in CHF.

【 授权许可】

Unknown   
© Chabot et al; licensee BioMed Central Ltd. 2011. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.